Neurology/CNS Phase 3 Deal Benchmarks — Ex-US (2026)
Median upfront of $232M with total deal values reaching $1.5B in Ex-US territory.
Median Upfront
$232M
Total Deal Value
$1.2B
Royalty Range
11.1%–17%
Territory Multiplier
0.45x
Understanding Neurology/CNS Deal Benchmarks at Phase 3
Phase 3 Neurology/CNS licensing deals in Ex-US territory command a median upfront payment of $232M, with values ranging from $141M at the low end to $313M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the neurology/cns therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $821M to $1.5B, with a median of $1.2B. Royalty rates for neurology/cns assets at this stage typically fall between 11.1% and 17% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Ex-US territory applies a 0.45x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating ex-us rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $141M | $232M | $313M |
| Total Deal Value | $821M | $1.2B | $1.5B |
| Royalty Rate | 11.1% | — | 17% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2023 | Takeda | Lundbeck | $100M | $800M | licensing |
| 2021 | Biohaven Pharmaceutical | Pfizer | $500M | $1.2B | licensing |
| 2017 | Teva | Otsuka | $50M | $65M | licensing |
| 2023 | Eli Lilly | Organon | $50M | $220M | licensing |
| 2023 | Idorsia | Mochida Pharmaceutical | $15M | $80M | licensing |
| 2024 | Idorsia | Viatris | $0M | $350M | licensing |
| 2024 | Simcere Pharmaceutical | Ono Pharmaceutical | $30M | $270M | licensing |
See All Comparable Deals
View 7 comparable Neurology/CNS transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Phase 3 Neurology/CNS deals in Ex-US territory?
How does Ex-US territory affect Neurology/CNS deal value?
What royalty rates are typical for Phase 3 Neurology/CNS licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$15M upfront
Neurology/CNS · Preclinical · Ex-US
$34M upfront
Neurology/CNS · Phase 1 · Ex-US
$105M upfront
Neurology/CNS · Phase 2 · Ex-US
$664M upfront
Neurology/CNS · Approved · Ex-US
$324M upfront
Oncology · Phase 3 · Ex-US
$406M upfront
Immunology · Phase 3 · Ex-US
$554M upfront
Metabolic/Obesity · Phase 3 · Ex-US
$515M upfront
Neurology/CNS · Phase 3 · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Neurology/CNS Phase 3 Deal Benchmarks — Ex-US (2026). Retrieved from https://solidus.ambrosiaventures.co/data/neurology-phase-3-deals-ex-us
<a href="https://solidus.ambrosiaventures.co/data/neurology-phase-3-deals-ex-us">Neurology/CNS Phase 3 Deal Benchmarks — Ex-US (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=neurology&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.